Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy (Q35753380)

10 August 2017

1 reference

title

Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy (English)

1 reference

amyotrophic lateral sclerosis

10 August 2017

main subject

1 reference

2

Patrick Weydt

1 reference

10 August 2017

Michael D Weiss

1

1 reference

10 August 2017

Gregory T Carter

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

735-746

1 reference

Amyotrophic lateral sclerosis is a multifactorial disease

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Disease progression in amyotrophic lateral sclerosis: predictors of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Visualising microglial activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Inflammatory processes in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Prostaglandins stimulate calcium-dependent glutamate release in astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

The effect of gabapentin on neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

A clinical trial of verapamil in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Marijuana in the management of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Efficient three-drug cocktail for disease induced by mutant superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.735

21 January 2018

Identifiers

DOI

10.1517/14656566.5.4.735

1 reference

10 August 2017

1 reference